
Ally Financial: In Gear
Ally Financial has rebounded strongly, with its stock climbing roughly 40% over the past year and doubling since the end of 2022. Adjusted earnings per share surged about 70% in Q1 FY26 to $4.3, and analysts project FY26 EPS near $5.3, a 125% increase from the FY24 trough. CFO Russ Hutchinson signaled confidence by purchasing roughly $1.5 million of shares, while the company executed a $150 million share buyback—the first in over three years. Proposed easing of capital rules could further enhance Ally’s balance‑sheet flexibility and support future returns.

Netflix: The Pace Of Change
Reed Hastings warned Netflix could stumble if it failed to transition from its DVD empire to streaming, a risk the company ultimately avoided by embracing on‑demand video. The author’s confidence in Netflix’s competitive edge has guided a four‑year investment that...

Chipotle: Recipe For Growth
Chipotle’s FY2025 results marked a sharp slowdown, with comparable sales down 1.7% and transaction comps falling 2.9%—the weakest performance in two decades. The decline was most pronounced in Q4, where comps slipped 2.5% and transactions fell 3.2%. In August 2024,...

Planet Fitness: Maxing Out?
Planet Fitness has expanded from a single Dover gym to roughly 2,900 clubs worldwide, with about 95% of locations in the United States and Canada. The chain now runs a franchise‑heavy model, where 2,600 clubs are owned by just 86...

Crocs: The HeyDude Hangover
Crocs has transformed from a niche clog maker into a $3.3 billion revenue powerhouse, selling roughly 129 million pairs in FY25 and lifting average selling prices from $19 to $25. The brand’s accessory line, Jibbitz, surged to over $250 million, a seven‑fold increase...

Q1 2026 Portfolio Update
The Science of Hitting reports that the S&P 500 slipped nearly 5% in Q1 2026, with the entire decline confined to March. Investors remain wary amid lingering macroeconomic and geopolitical headwinds. The blog notes a similar Q1 dip in 2025, which...

Fever-Tree: "A Pivotal Moment"
Fever‑Tree’s U.S. tonic market share climbed to roughly 28% in 2025, driven by its partnership with Molson Coors and aggressive marketing spend. In the U.K., the once‑dominant tonic line shrank to about 20% of revenue, with sales falling from roughly $151 million...

How Is This Possible?
The episode dissects Tripadvisor’s shocking Q4 FY25 results, which sent the stock tumbling below $10—a historic low—following a 2025 merger that eliminated a controlling shareholder. Host examines activist investor Jeff Smith’s aggressive push for strategic change, highlighted by his pointed...
Netflix: Waning Optimism
The episode reviews the author's evolving stance on Netflix, noting a recent 200‑basis‑point trim to the stock after several reductions throughout 2024, signaling waning optimism. Despite the cut, Netflix still comprises about 8% of the portfolio, reflecting lingering confidence in...